Your shopping cart is currently empty

Carperitide acetate (Atrial Natriuretic Peptide (ANP) (1-28), human, porcine Acetate), a 28-amino acid hormone, is naturally produced and released by the human heart upon cardiac injury or mechanical stretch. This compound effectively inhibits the secretion of endothelin-1 in a dose-dependent manner.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $195 | In Stock | In Stock | |
| 5 mg | $483 | In Stock | In Stock | |
| 10 mg | $691 | In Stock | In Stock | |
| 25 mg | $1,080 | In Stock | In Stock | |
| 50 mg | $1,460 | In Stock | In Stock | |
| 100 mg | $1,970 | - | In Stock | |
| 200 mg | $2,660 | - | In Stock |
| Description | Carperitide acetate (Atrial Natriuretic Peptide (ANP) (1-28), human, porcine Acetate), a 28-amino acid hormone, is naturally produced and released by the human heart upon cardiac injury or mechanical stretch. This compound effectively inhibits the secretion of endothelin-1 in a dose-dependent manner. |
| In vitro | Atrial natriuretic peptide (ANP), isolated from mammalian hearts, exhibits diuretic, natriuretic, and vasodilatory properties. It has been observed that porcine ANP (1-28) not only inhibits the secretion of immunoreactive endothelin-1 in porcine endothelial cells and aorta upon stimulation with Angiotensin II (Ang II) but also elevates cellular cGMP levels. Similarly, human ANP (1-28) suppresses immunoreactive endothelin-1 secretion and enhances cyclic GMP in human umbilical-vein endothelial cells when stimulated by angiotensin II (ANGII) and thrombin. Moreover, in normal rat glomeruli, Human 125I-ANP (1-28) binds to high-affinity receptors, significantly increasing cGMP without affecting cAMP, showcasing its integral role in electrolyte and fluid homeostasis[1,2,3]. |
| Synonyms | Carperitide acetate (89213-87-6 Free base), Atrial Natriuretic Peptide (ANP) (1-28), human, porcine Acetate |
| Molecular Weight | 3140.5 |
| Formula | C129H207N45O41S3 |
| Smiles | C(C)(O)=O.[C@H](CC1=CC=CC=C1)(C(N[C@H](C(N[C@@H](CC2=CC=C(O)C=C2)C(O)=O)=O)CCCNC(=N)N)=O)NC([C@@H](NC([C@@H](NC(=O)[C@@H]3CSSC[C@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CO)N)=O)CC(C)C)=O)CCCNC(=N)N)=O)CCCNC(=N)N)=O)CO)=O)CO)=O)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@]([C@H](CC)C)(C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N3)[H])CC(N)=O)=O)CO)=O |
| Relative Density. | no data available |
| Sequence | Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Met-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr (Disulfide bridge: Cys7-Cys23) |
| Sequence Short | SLRRSSCFGGRMDRIGAQSGLGCNSFRY (Disulfide bridge: Cys7-Cys23) |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 240 mg/mL (76.42 mM) H2O: 100 mg/mL (31.84 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
H2O/DMSO
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.